iBB

While Lactococcus lactis is traditionally associated with the fermented food industry, applications of these bacteria have been spreading to the pharmaceutical industry. The goal is to use L. lactis as cell factories for the production of added-value recombinant proteins and plasmid DNA (pDNA) for DNA vaccination, as a safer and industrially profitable alternative to the traditional Escherichia coli host. In a recent review in International Molecular Sciences, Sofia Duarte and Gabriel Monteiro from BERG-iBB critically systematize the plasmid replicons available for the production of pharmaceutical-grade pDNA and recombinant proteins by L. lactis. The work is funded by the LactoSynt project.